Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olodanrigan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 known ✓ | P50052 | 19/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olodanrigan SCHEMBL421411 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL244657 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| Olodanrigan SCHEMBL29394365 | 1.00 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964206 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516607 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL8964101 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3514261 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL3519228 | 0.94 | AGTR2 (1.00) | AGTR2AGTR1 | |
| SCHEMBL3516610 | 0.94 | AGTR2 (0.88) | AGTR2AGTR1 | |
| SCHEMBL3517015 | 0.92 | AGTR2 (0.87) | AGTR2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595960-B1 | SALT AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | NOVARTIS AG (CH) | 2016-02-24 | — | — | EP | disclosed |
| US-9162985-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-04-16 | — | — | US | disclosed |
| US-8927575-B2 | Salts and solvates of a tetrahydroisoquinoline derivative | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2015-01-06 | — | — | US | disclosed |
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-03-20 | — | — | US | disclosed |
| US-5525614-A | TREATING VASCULAR RESTENOSIS, CNS DISORDERS | WARNER-LAMBERT COMPANY (US) | 1996-06-11 | — | — | US | disclosed |
| US-5489686-A | CARDIOVASCULAR DISORDER, NERVOUS SYSTEM DISORDER, ANTIDIURETIC , PSYCHLOGICAL DISORDER, ANTIDEPRESSANTS | WARNER-LAMBERT COMPANY (US) | 1996-02-06 | — | — | US | disclosed |
| US-5350757-A | Treatment of vascular restenosis, nervous system disorders and cognition enhancement | WARNER-LAMBERT COMPANY (US) | 1994-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080865-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 126/4885AGTR1 181/4885 |
| US-20150105422-A1 | SALTS AND SOLVATES OF A TETRAHYDROISOQUINOLINE DERIVATIVE | SUDS3, REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | AGTR2 126/4885AGTR1 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.